Immune-Related Adverse Events for GI Toxicity - Hepatitis
Grades severity of hepatitis secondary to immune checkpoint inhibitor therapy.
INSTRUCTIONS
Use in adult patients with symptoms of hepatitis or AST, ALT, or total bilirubin elevation that developed while on treatment with immune checkpoint inhibitors.
When to Use
Pearls/Pitfalls
Why Use
Asymptomatic (AST or ALT > ULN to 3.0 x ULN and/or total bilirubin > ULN to 1.5 x ULN)
Asymptomatic (AST or ALT > ULN to 3.0 to 5 x ULN and/or total bilirubin >1.5 to ≤3 x ULN)
Symptomatic liver dysfunction, fibrosis by biopsy, compensated cirrhosis, reactivation of chronic hepatitis (AST or ALT 5-20 x ULN and/or total bilirubin 3-10 x ULN)
Decompensated liver function leg, ascites, coagulopathy, encephalopathy, coma; AST or ALT >20 x ULN and/or total bilirubin >10 x ULN)
Result:
Please fill out required fields.